Adenosine A2A receptor (A2AR) neurons represent a distinct population of striatal medium spiny neurons (MSNs) that co-express the adenosine A2A receptor. These neurons are primarily located in the indirect pathway of the basal ganglia and play a crucial role in motor control, reward processing, and neuroprotection[1][2]. A2A receptors are G protein-coupled receptors that couple to Gs/olf proteins, leading to increased intracellular cAMP levels and excitatory signaling.
| Property |
Value |
| Category |
Striatal Medium Spiny Neurons |
| Location |
Striatum (indirect pathway) |
| Neurotransmitter |
GABA |
| Receptor |
Adenosine A2A Receptor |
The A2A receptor is a G protein-coupled receptor (GPCR) with distinct pharmacological and anatomical properties:
- Gene: ADORA2A
- Protein family: Adenosine receptor family (A1, A2A, A2B, A3)
- G protein coupling: Gs/olf (stimulatory)
- Signal transduction: ↑ cAMP, ↑ PKA activity
- Distribution: Highly enriched in striatum, especially in indirect pathway MSNs
A2A-expressing MSNs are characterized by:
- D2 dopamine receptor: Co-expressed with A2AR (defines indirect pathway)
- Enkephalin: High expression in A2A neurons
- Substance P: Low expression (more in direct pathway)
- DARPP-32: Phosphoprotein enriched in MSNs
A2A receptor neurons are integral to the indirect pathway[^3]:
- Input: Receive excitatory cortical input via glutamatergic synapses
- Output: GABAergic projections to the external globus pallidus (GPe)
- Effect: Movement suppression, action stopping
A2A neurons modulate motor behavior through:
- Movement initiation: Oppose direct pathway, provide braking function
- Motor learning: Critical for habit formation and reinforcement
- Bradykinesia: A2A antagonists improve motor function in PD
¶ Reward and Motivation
A2A receptors modulate dopaminergic signaling in reward circuits[^4]:
- Striatal reward pathways: A2A-D2 receptor interactions regulate reward learning
- Motivation: A2A activity influences motivational states
- Addiction: A2A receptors implicated in substance use disorders
A2A MSNs have distinctive electrophysiological properties:
| Property |
Value |
| Resting membrane potential |
-70 to -80 mV |
| Input resistance |
~100 MΩ |
| Action potential duration |
~1.5 ms |
| Firing pattern |
Low-frequency tonic, pause-field-pause |
- Up states: Depolarized membrane potentials during active states
- Down states: Hyperpolarized resting states
- Synaptic integration: Strong corticostriatal inputs
A2A receptors are major therapeutic targets in PD[^5]:
- A2A antagonists: Istradefylline (KW-6002) approved for PD treatment
- Motor benefits: Improve bradykinesia and reduce OFF time
- Neuroprotection: A2A antagonism may protect dopaminergic neurons
- Rationale: Blocking A2A removes brake on motor output
- A2A dysfunction: Altered A2A receptor expression in HD
- Therapeutic potential: A2A modulators may improve motor symptoms
- Neuroprotection: A2A antagonism reduces excitotoxicity
- Depression: A2A receptors implicated in mood regulation
- Anxiety: A2A modulation affects anxiety-like behaviors
- Sleep: A2A receptors promote sleep, especially slow-wave sleep
- A2A-D2 antagonism: A2A and D2 receptors form heteromers with antagonistic interactions[^6].
- Selective antagonists: Caffeine and istradefylline produce motor activation by blocking A2A.
- Gene therapy: A2A overexpression in striatum produces parkinsonian phenotypes.
- Istradefylline: FDA-approved A2A antagonist for PD adjunct therapy
- Preclinical compounds: Selective A2A agonists/antagonists in development
- Combination therapy: A2A antagonists with L-DOPA or DBS
- Schiffmann et al. Adenosine A2A receptors in basal ganglia (2007)
- Cunha et al. Adenosine receptors as neuromodulators (2008)
- Gerfen. Indirect pathway MSNs (1992)
- Ferré et al. A2A-D2 receptor interactions in reward (2010)
- Kase. A2A antagonists in Parkinson's disease (2003)
- Fuxe et al. A2A-D2 receptor heteromers (2005)